

In western Countries cancers of the breast, endometrium and ovary represent the most common malignant neoplasms of women. These cancers show several points of interaction such as the common germ-line genetic defects predisposing to hereditary breast and ovarian cancers (HBOC).

The increased risk of endometrial cancer conferred by the use of selective estrogen modulators given as an adjuvant treatment to breast cancer patients, the possible metastatic involvement of the ovary seldom observed in breast cancer patients and finally the increased incidence of the cancer of endometrium in families with hereditary non-polyposis colorectal cancers (HNPCC).

The ongoing evolution of technology allows an ever-increasing sub-classification of cancers unraveling more targeted approaches and new therapeutic possibilities, for example with the use of PARP inhibitors in cancers with impaired DNA repair mechanisms.

For cancers of the endometrium and of the ovary the surgeon still plays a major role. However, neoadjuvant platinum-based chemotherapy followed by interval debulking surgery is a viable option for stage IV and bulky stage III patients for whom the obtainment of an optimal debulking with up front surgery is deemed unlikely. Furthermore, the extent of staging lymphadenectomy in endometrial cancer and the role of intraperitoneal chemotherapy in ovarian cancers still deserve discussion.

All these observations underscore the need of a multi-disciplinary approach, in which surgeons, gynecologists, pathologists, geneticists and medical oncologists are actively involved to tailor the best treatment for each individual patient.

This meeting is jointly organized by the Departments of Medical Oncology at the Ospedale Mater Salutis-Legnago, Azienda Ospedaliera Universitaria Integrata-Verona and New York University and brings together leaders in the field from Italy and the USA.

<http://meeting-eventi.com/oncology>

Maximum number of attendees is 150 people
FREE REGISTRATION within 15th March 2015

CME Provider



MEETING PLANNER
Provider ECM Nazionale Accreditato n. 2516
Via Alberotanza, 5 - 70125 BARI
TEL. 080.9905360 - FAX 080.9905359 - 080.2140203
E-mail: info@meeting-planner.it - www.meeting-planner.it



ACCREDITAMENTO ECM (evento n. 117232)

Il Provider ha attribuito all'evento n. 6,8 crediti formativi.

L'evento formativo è rivolto a n. 150 partecipanti tra Infermieri, Farmacisti, Medici Chirurghi specialisti in: Genetica Medica, Oncologia, Chirurgia Generale, Ginecologia e Ostetricia, Anatomia Patologica.

Si rende noto che ai fini dell'acquisizione dei crediti formativi ECM e relativo invio dell'attestato è obbligatorio:

- aver preso parte all'intero evento formativo
- aver compilato la documentazione in ogni sua parte
- aver superato il questionario di valutazione ECM (score di superamento : 75%).

Il Provider è autorizzato a verificare l'effettiva presenza tramite firme

Si ricorda che la certificazione non potrà essere rilasciata in caso di: registrazioni dopo l'orario d'inizio, uscita anticipata rispetto alla fine dei lavori, consegna del questionario ECM a mezzo terzi. Il Partecipante è tenuto a rispettare l'obbligo di reclutamento diretto fino ad un massimo di 1/3 dei crediti formativi ricondotti al triennio di riferimento (2014-2017). Non sono previste deroghe a tali obblighi.

OBBIETTIVO FORMATIVO DI SISTEMA: APPLICAZIONE NELLA PRATICA QUOTIDIANA DEI PRINCIPI E DELLE PROCEDURE DELL'EVIDENCE BASED PRACTICE (EBM - EBN - EBP) (1)

Organizing Secretariat

RENBEL GROUP MEETING & EVENTS by Renbel Travel srl

Via Valpolicella, 1 - 37124 Verona

Phone: +39 045 770 11 50 - Fax: +39 045 942 022

E-mail: eventi@renbelgroup.it - www.renbelgroup.com

The following companies are supporters of the Congress

AMGEN

AstraZeneca

B BRAUN
SHARING EXPERTISE

BIOMARIN



IPSEN
Innovation for patient care

Lilly

NOVARTIS
ONCOLOGY

Pharma
Mar
Grupo Zeltia

Pierre Fabre
Pharma

Roche



AZIENDA OSPEDALIERA
UNIVERSITARIA INTEGRATA
VERONA



NYU Langone
MEDICAL CENTER

WOMEN'S CANCERS 2015

Verona - 23th March 2015

Centro Medico Culturale Marani



A.N.D.O.S.
(Associazione Nazionale
Donne Operate al Seno)
Comitato di Verona

supported by

GOIRC
GRUPPO ONCOLOGICO ITALIANO
DI RICERCA CLINICA

8.00-8.30 Attendees registration
 8:30-8:50 Introduction
 Andrea Bonetti, Franco Muggia, Giampaolo Tortora

SESSION 1 Ovarian and Endometrial Cancers

Chairmen: Pietro Catapano, Erminia Manfrin

8.50 - 9.10 Pathology and molecular classification
 Elena Piazzola

9.10 - 9.30 Optimal surgical treatment of endometrial cancer
 Cesare Romagnolo

9.30 - 9.50 Optimal surgical treatment of ovarian cancer
 Massimo Franchi

9.50 - 10.10 Peritonectomy & HIPEC
 Giovanni De Manzoni

10.10 - 10.30 Update on chemotherapy for endometrial cancer
 Franco Muggia

10.30 - 10.50 Update on chemotherapy for ovarian cancer
 Nicoletta Colombo

10.50-11.10 Lecture: PARP Inhibitors
 Hilary H Calvert

11.10-12.00 Discussion

12.00-13.00 Lunch

SESSION 2 Breast cancers

Chairmen: Andrea Remo, Ernesto Laterza

13.00 - 13.20 Breast cancer: an overview
 Franco Bonetti

13.20 - 13.40 Breast cancer and obesity
 Anna Mercanti

13.40 - 14.00 Druggable molecular pathways
 Giampaolo Tortora

14.00-14.20 Hormonal therapy and hormone-resistance
 in ER-positive Her 2-negative Breast Cancers
 Andrea Bonetti

14.20 - 14.40 New agents for Her 2 positive breast cancers
 Francisco Esteva

14.40 - 15.00 Optimal therapy for Triple Negative breast
 cancers
 Eleni Andreopoulou

15.00 - 15.40 Challenging cases
 Marta Mion, Oliviero Puccetti

15.40-16.30 Discussion

16.30 - 17.00 Coffee Break

SESSION 3 Hereditary breast and ovarian cancers (HBOC)

Chairmen: Alberto Turco, Roberto Leone

17.00 - 17.30 Patient's advocacy
 Valerie Smaldone

17.30 - 17.45 The HBOC clinic at the Mater Salutis Hospital
 Filippo Greco, Maria Paola Cecchini

17.45 - 18.15 Dealing with advanced BRCA-positive
 breast cancers: Panel discussion

18.15 - 18.45 Challenging cases
 Cristina Oliani, Paolo Morandi, Antonella Ferro

18.45 - 19.00 Closing remarks
 Pierfranco Conte

Eleni Andreopoulou Albert Einstein College of Medicine,
 New York USA

Andrea Bonetti Azienda Ulss 21 Legnago, Verona Italy

Franco Bonetti Università di Verona, Italy

Hilary Calvert UCL Cancer Institute, London UK

Pietro Catapano Azienda Ulss 21 Legnago, Verona Italy

Maria Paola Cecchini Università di Verona, Italy

Nicoletta Colombo Istituto Europeo di Oncologia,
 Milano Italy

Pierfranco Conte Istituto Oncologico Veneto,
 Padova Italy

Giovanni De Manzoni Università di Verona, Italy

Francisco J. Esteva NYU Langone Medical Center,
 New York USA

Antonella Ferro Presidio Ospedaliero Santa Chiara,
 Trento Italy

Massimo Franchi AOUI, Verona Italy

Filippo Greco Azienda Ulss 21 Legnago, Verona Italy

Ernesto Laterza Azienda Ulss 21 Legnago, Verona Italy

Roberto Leone Università di Verona, Italy

Erminia Manfrin Università di Verona, Italy

Anna Mercanti Azienda Ulss 21 Legnago, Verona Italy

Marta Mion Ospedale Camposampiero, Padova Italy

Paolo Morandi Ospedale di Venezia, Italy

Franco M. Muggia NYU Langone Medical Center,
 New York USA

Cristina Oliani Ulss 5 Ovest Vicentino, Vicenza Italy

Elena Piazzola Università di Verona, Italy

Oliviero Puccetti Ulss 4, Vicenza Italy

Andrea Remo Azienda Ulss 21 Legnago, Verona Italy

Cesare Romagnolo Azienda Ulss 20, Verona Italy

Valerie Smaldone Media Worldwide LLC

Giampaolo Tortora AOUI, Verona Italy

Alberto E. Turco Università di Verona, Italy

Scientific Committee

Dott. Andrea Bonetti
 AULSS 21 (Legnago) Verona

Prof. Franco M. Muggia
 NYU Langone Medical Center New York USA

Prof. Giampaolo Tortora
 Azienda Ospedaliera Universitaria Integrata Verona